Dyslipidemia and XXXX : animal models.

@entity2175 @entity2298 @entity407 @entity137 @entity1007 @entity6 @entity28 @entity3839 @entity95 @entity1723 @entity3190 @entity35 @entity731 @entity1720 @entity65 @entity165
Many models of @entity6 are available. Animals with chemically-induced @entity6 have been used to study @entity1723 . @entity1007 in @entity3839 -induced @entity6 in @entity35 results from increased intestinal absorption and synthesis of @entity165 . Lipoproteins from @entity6 @entity35 are oxidized and demonstrate @entity137 , a feature which can be prevented by insulin or antioxidant treatment. @entity6 @entity95 fed a @entity165 -rich diet do not develop @entity731 because accumulated VLDL are apo E-depleted, too large and do not enter into the arterial wall. Models for @entity2175 ( @entity2175 ) are obtained through selective breeding or dietary conditions. The @entity28 Zucker @entity35 (fa/fa) is characterized by hyperphagy, hyperglycaemia, @entity3190 , @entity1720 , @entity2298 and hypercholesteolemia. It responds to dietary, hormonal and drug treatments, but does not develop @entity731 spontaneously. It is used as a model for @entity28 , @entity2175 and type IV @entity407 . The JCR:LA cp @entity35 bears the corpulent gene and develops similar characteristics to those of the Zucker @entity35 . However, @entity1720 is more severe in homozygous males (cp/cp), and @entity65 are observed. Their appearance is reduced by treatments which decrease @entity3190 and insulin resistance but not by lowering lipid levels alone. The sand @entity35 (Psammomys obesus) develop @entity28 and @entity2175 when fed a laboratory diet. When @entity165 and anti-thyroid drug are added to the diet, they develop @entity65 . This species constitutes a new model for studying @entity731 -related @entity6 .
